Science & Innovation

Pipeline

Dorzagliatin

mGluR5

Poster and Presentation

Peer Reviewed Publications

Announcements and Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock Information

Corporate Communications

Portfolio Advisory Board

Senior Scientific Advisory Board

Media

Company News

Dec 21

2023

Hua Medicine Announces Submission of Investigational New Drug Application with U.S. FDA

Hua Medicine (HKEx:2552HK) announced today that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for its 2nd generation glucokinase allosteric activator (2nd Gen GKA) to initiate a Phase I randomized, double-blinded, placebo-controlled, single-dose, safety, tolerability, pharmacokinetic, and pharmacodynamic study in subjects with Type 2 diabetes mellitus (T2D) in the United States.

Dec 13

2023

[News] Hua Medicine Announces the Inclusion of Dorzagliatin in the National Reimbursement Drug List (NRDL)

Hua Medicine (the "Company", HKEx: 2552.HK) announced today that HuaTangNing (华堂宁®) (dorzagliatin), its self-developed first-in-class glucokinase allosteric activator (GKA) for diabetes, has been successfully included in China's National Reimbursement Drug List (NRDL) by the National Healthcare Security Administration (NHSA).

Nov 23

2023

[News] Hua Medicine to Present Research Findings at CDS 2023

Hua Medicine (HK:2552) today announced that it will present multiple research findings at the 25th Scientific Meeting of the Chinese Diabetes Society (CDS 2023).

Aug 24

2023

[News]Hua Medicine Announces 2023 Interim Results

Hua Medicine (the "Company", HKEx: 2552) today announces the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2023 (the "Reporting Period").

Aug 17

2023

New publication shines spotlight on Hua Medicine's Dorzagliatin ability to achieve diabetes remission over 52-week period

Shanghai, 17 August 2023 – Sending Type 2 diabetes into remission is now a possibility thanks to Hua Medicine's HuaTangNing1 (华堂宁®) (dorzagliatin), as reported in a new published paper based on data from a 52-week study.

Jun 26

2023

[News] Hua Medicine Announces the Potential of Dorzagliatin in Cognitive Dysfunction at ADA 2023

Hua Medicine (the "Company", HKEx stock code: 2552) today announces that multiple basic and clinical findings of HuaTangNing (华堂宁®, dorzagliatin), the Company’s global first-in-class glucokinase activator (GKA), were presented at the 83rd American Diabetes Association (ADA) Annual Scientific Sessions.

Jun 16

2023

[News] Hua Medicine will present multiple research results at the 2023 American Diabetes Association (ADA) Annual Scientific Sessions

Hua Medicine (the "Company", HKEx stock code: 2552) announced today that it will present multiple research results of HuaTangNing (华堂宁®, dorzagliatin), the Company’s first-in-class glucokinase activator (GKA), at the 83rd American Diabetes Association (ADA) Annual Scientific Sessions.

Mar 30

2023

[News] Hua Medicine Announces Multiple Personnel Appointments

Hua Medicine (the "Company", stock code: 2552.HK) today announces that Mr. George Chien Cheng Lin has been appointed Chief Strategy Officer of Hua Medicine. Mr. Lin will assume responsibility for corporate strategy for the Company, in addition to his current responsibilities for business development

Mar 30

2023

[News] Hua Medicine Announces 2022 Annual Results

Hua Medicine (the "Company", HKEx stock code: 2552), announced the audited consolidated results of the Company and its subsidiaries for the year ended December 31, 2022 (the "Reporting Period"). During the Reporting Period, the Company has achieved breakthrough development

About Us

Company Overview

Company History

Leadership Team

Portfolio Advisory Board

Senior Scientific Advisory Board

Partner

Media center

Research & Development

Inovation

Pipeline

Dorzagliatin

mGluR5

Company Publications

Peer Reviewed Publications

Investor Relations

Corporate Governance

Financial Report

Announcements & Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock information

Media

Company News

Media Releases

Video

Careers

Culture

Join Us

Product

HuaTangNing(华堂宁®)

Focus Us

沪公网安备 31011502013809号 Privacy Statement Terms of Use

How we use cookies

Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.